Table 1 Adverse Events and Clinical Outcomes of DAB/IL2 Administration to Melanoma Patients
From: Transient T cell depletion causes regression of melanoma metastases
ID | Age | M/F | Stage | Cycles | Adverse Events (grade) | Outcome(s) | HLA-A2* 0201 | CD8+ T Cells |
|---|---|---|---|---|---|---|---|---|
P1 | 50 | F | IV | 2 | Erythema (1) | Progressive disease | - | Not applicable |
P2 | 78 | M | IV | 3 | Weakness (1) | Progressive Disease | - | Not applicable |
P3 | 58 | M | IV | 4 | None | Mesenteric & Hepatic Regressions (PR) | - | Not applicable |
P4 | 66 | F | IV | 1 | None | Progressive Disease | - | Not applicable |
P5 | 72 | M | IV | 2 | Pain at tumor site (1) | R. Hilar and Colon Regressions (PR) | - | Not applicable |
P6 | 63 | M | IV | 2 | None | Progressive Disease | - | Not applicable |
P7 | 67 | M | IV | 4 | None | Progressive Disease | + | MART1+Tyr+ |
P8 | 58 | F | IV | 4 | None | IM & SC Regressions (PR) | - | Not applicable |
P9 | 46 | M | IV | 4 | None | Inguinal Regression | + | MART1+g100+ Tyr+ |
P10 | 35 | F | IV | 3 | None | Progressive Disease | + | Negative |
P11 | 54 | M | IV | 2 | None | Progressive Disease | + | Negative |
P12 | 79 | M | IV | 2 | Dermatitis (2) | Stable Disease | - | Not applicable |
P13 | 72 | M | IV | 1 | Dehydration (2) | Progressive Disease | - | Not applicable |
P14 | 61 | M | IV | 4 | Vitiligo (1) | Pulmonary, Hepatic, LN & SC Regressions (PR) | + | MART1+ |
P15 | 46 | F | IV | 4 | None | Progressive Disease | + | Negative |
P16 | 68 | F | IV | 4 | Arthritis (2) Dermatitis (1) | Progressive Disease | + | MART1+g100+ Tyr+ |